<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313104</url>
  </required_header>
  <id_info>
    <org_study_id>NU 10G02</org_study_id>
    <secondary_id>NCI-2011-00112</secondary_id>
    <secondary_id>STU00039225</secondary_id>
    <nct_id>NCT01313104</nct_id>
  </id_info>
  <brief_title>Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer</brief_title>
  <official_title>Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies colposcopy and high resolution anoscopy in screening for anal
      dysplasia in patients with cervical, vaginal, or vulvar dysplasia or cancer. Screening may
      help doctors find cancer cells early and plan better treatment for cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. To evaluate the risk of anal dysplasia in women with cervical or vulvar dysplasia.

      OUTLINE:

      Patients undergo colposcopy and cervical Papanicolaou test with Human papillomavirus (HPV)
      test followed by anal Papanicolaou test and high resolution anoscopy. Patients with
      dysplastic anal lesions undergo repeat anoscopy at 3, 9, 15, and 24 months. Patients with
      normal anoscopy are followed up at 1 and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of anal dysplasia in women with cervical or vulvar dysplasia</measure>
    <time_frame>Over 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV (Human Papillomavirus) status</measure>
    <time_frame>Over 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 1</condition>
  <condition>Cervical Intraepithelial Neoplasia Grade 2</condition>
  <condition>Cervical Intraepithelial Neoplasia Grade 3</condition>
  <condition>Recurrent Cervical Cancer</condition>
  <condition>Recurrent Vaginal Cancer</condition>
  <condition>Recurrent Vulvar Cancer</condition>
  <condition>Stage 0 Cervical Cancer</condition>
  <condition>Stage 0 Vaginal Cancer</condition>
  <condition>Stage 0 Vulvar Cancer</condition>
  <condition>Stage I Vaginal Cancer</condition>
  <condition>Stage I Vulvar Cancer</condition>
  <condition>Stage IA Cervical Cancer</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage II Vaginal Cancer</condition>
  <condition>Stage II Vulvar Cancer</condition>
  <condition>Stage IIA Cervical Cancer</condition>
  <condition>Stage IIB Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage III Vaginal Cancer</condition>
  <condition>Stage III Vulvar Cancer</condition>
  <condition>Stage IV Vulvar Cancer</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <condition>Stage IVA Vaginal Cancer</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <condition>Stage IVB Vaginal Cancer</condition>
  <arm_group>
    <arm_group_label>Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colposcopy</intervention_name>
    <description>Undergo colposcopy</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cervical Papanicolaou test</intervention_name>
    <description>Undergo cervical Pap smear</description>
    <arm_group_label>Screening</arm_group_label>
    <other_name>cervical Pap test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>screening method</intervention_name>
    <description>Undergo anal Pap smear</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>screening method</intervention_name>
    <description>Undergo high resolution anoscopy</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of cervical, vaginal or vulvar intraepithelial neoplasia or
             cancer are included

          -  Individuals treated with prior radiation therapy and/or chemotherapy are allowed

          -  Women with high-grade dysplasia (carcinoma in situ) are eligible, regardless of their
             dysplasia free interval

          -  HIV-positive (Human Immunodeficiency Virus) and HIV-negative women will be enrolled;
             HIV testing will not be performed as part of the study

        Exclusion Criteria:

          -  Women who are not able to consent are excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Halverson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

